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CP and IM have made substantial contributions to the conception and writing of the protocol. IT, GK, AA and AT contributed in reviewing and writing the protocol. All authors read and approved the final manuscript.

The Thy-Support trial will be entirely financially supported by Uni-Pharma S.A. (Greece) including materials used in this study. Uni-Pharma S.A. will have full oversight of the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. The sponsor will also fund the CRO (PHARMASSIST) which will undertake collection, analysis, and interpretation of data in collaboration with a Data Monitoring Committee.

The Data Monitoring Committee will have access to the final trial dataset. The data will be available from the corresponding author on reasonable request and upon permission from the sponsor of the study.

The National Ethics Committee of the Greek Drug Administration has approved the study. The file number/reference number of the ethical approval judgement is 45309/2020, date of approval 21 May 2020). Link to the public listing of the ethical approval, 41/20: <http://www.eof.gr/c/document_library/get_file?uuid=83ab5dde-fded-4aa3-ba2a-96a958b66047&groupId=12225>

We certify that this trial has received ethical approval from the appropriate ethical committee.

All patients participating in the study or their legal representative will provide signed informed consent.
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The following pending patents are relevant to the work in this manuscript

• PCT/EP2019/087056. L-triiodothyronine (T3) for use in limiting microvascular obstruction

• Greek Patent Office, number of case: 22-0002577373. Composition comprising L-triiodothyronine (T3) for use in the treatment of critically ill patients with coronavirus infection.

IT, managing director of Uni-Pharma, is the sponsor and owner of these patents. CP and IM are the inventors and hold royalties in relation to these patents.
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